异quercitrin:从自然来源到临床候选人 - 合成,药理学和代谢安全性
Bocui Song1, Wenqi Niu1, Haice Sun1
1College of Life Science and Technology, Heilongjiang Bayi Agricultural University, Daqing, Heilongjiang, China.
Fitoterapia
|July 30, 2025
概括
异quercitrin (ISQ) 是一种具有广泛治疗潜力的植物类黄. 本综述详细介绍了其机制,包括抗氧化和抗炎途径,并强调需要改善口服生物可用性.
科学领域:
- 药理学和自然产品化学化学
- 生物化学和分子生物学
背景情况:
- 异quercitrin (ISQ) 是一种在各种植物中发现的黄类化合物.
- ISQ在多个身体系统中表现出显著的治疗效果.
- 现有的研究突出了ISQ的潜力,但需要进行全面的分析.
研究的目的:
- 系统地审查Isoquercitrin (ISQ) 的药理机制,毒性,合成和药理动力学.
- 巩固有关ISQ生物活动和治疗应用的当前知识.
- 确定未来的研究方向和ISQ的临床翻译途径.
主要方法:
- 在Web of Science,谷歌学者,科学直播和PubMed (2015年至今) 的系统文献搜索.
- 根据纳入标准选了1694篇文章,其中117篇研究被选中进行分析.
- 对药理机制,毒性,合成方法和药理动学的全面评估.
主要成果:
- 通过JAK/STAT3,Nrf2/ARE,NF-κB,AMPK,PI3K/Akt和Wnt通路,ISQ产生影响.
- 显示出抗炎,抗氧化,代谢调节和瘤抑制的特性.
- 诱导选择性癌细胞死亡,并表现出较低的口服生物利用性,需要改进配方.
结论:
- 异quercitrin (ISQ) 具有由复杂的分子机制驱动的多方面的药理活动.
- 进一步的研究和配方开发对于优化ISQ的治疗疗效和临床应用至关重要.
- 本综述提供了ISQ当前研究环境的全面概述.
相关概念视频
Preclinical Development: Overview
4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Drug Discovery: Overview
8.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.8K
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Insulin: Biosynthesis, Chemistry, and Preparation
554
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
554
Clinical Trials
8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.5K
Therapeutic Index
5.1K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
5.1K


